Laidlaw & Company (UK) Ltd.
March 20, 2017
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Washington, DC 20549
| Re: | THERAPIX BIOSCIENCES LTD. | |
| Registration Statement on Form F-1 (Registration No. 333-214458) | ||
| Concurrence in Acceleration Request |
Ladies and Gentlemen:
Laidlaw & Company (UK) Ltd. (“Laidlaw”), as representative of the underwriters for the referenced offering, hereby concurs in the request by Therapix Biosciences Ltd. that the effective date of the above-referenced registration statement be accelerated to 4:30 p.m. (Eastern Time), or as soon as practicable thereafter, on March 21, 2017 pursuant to Rule 461 under the Securities Act. Laidlaw affirms that it is aware of its obligations under the Securities Act in connection with this offering.
| Very truly yours, | ||
| Laidlaw & Company (UK) Ltd. | ||
| By: | /s/ Hugh Regan | |
| Name: Hugh Regan Title:Executive Director | ||
